Evidence map›Paper›PMID 38265774›Full record

SynthesisJAMA dermatology2024

Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review.

Lourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, Sarem Rashid, Andrew Creadore, Brian Chu, Camila Villa, Michael J Woodbury, April W Armstrong, Vibeke Strand and 3 more

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in JAMA dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Psoriasis.Nature reviews. Disease primers · 2025
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Lourdes M Pérez-ChadaDepartment of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Zachary H HopkinsDepartment of Dermatology, University of Utah, Salt Lake City.
Deepak M W BalakDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
Sarem RashidDepartment of Dermatology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Andrew CreadoreDepartment of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Brian ChuDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Camila VillaDepartment of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Michael J WoodburyDepartment of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
April W ArmstrongDepartment of Dermatology, University of California, Los Angeles, Los Angeles.
Vibeke StrandDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California.
Alice B GottliebDepartment of Dermatology, Icahn School of Medicine at Mt Sinai, New York, New York.
Joseph F MerolaDivision of Rheumatology, Department of Dermatology and Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
John S BarbieriDepartment of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital · USBoston University · USIcahn School of Medicine at Mount Sinai · USLeiden University Medical Center · NLStanford University · USUniversity of California, Los Angeles · USUniversity of Pennsylvania · USUniversity of Utah · US

Funding

Applying Item Response Theory to Improve Patient Reported Outcome Use in Dermatology Clinical PracticeK23AR078930 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI John Barbieri · 2022 to 2026
$867k
NIAMS NIH HHS K23 AR078930
6 · The paper itself

Abstract

Importance: Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use. Objective: To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis. Evidence Review: Using PubMed and Embase, full-text articles published in English or Spanish on development or validation studies for psoriasis-specific, dermatology-specific, or generic HRQL PROMs were included. Development studies included original development studies, even if not studied in psoriasis patients per Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations. If a study included multiple diagnoses, more than 50% of patients had to have psoriasis or psoriasis-specific subgroup analyses available. Data extraction and analysis followed the COSMIN guidelines. Two independent reviewers extracted and analyzed the data, including PROM characteristics, quality of measurement properties (structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity, and responsiveness), and level of evidence. PROMs were classified into 3 levels of recommendations: (1) PROM recommended for use; (2) PROM requires further validation; and (3) PROM not recommended for use. Findings: Overall, 97 articles were identified for extraction. This included 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs. According to COSMIN standards, most measures identified received a B recommendation for use, indicating their potential but requiring further validation. Only the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch) received an A recommendation for use given that it had sufficient content validity, structural validity, and internal consistency. Conclusions and Relevance: This study identified a significant lack of information concerning the quality of HRQL measures in psoriasis. This gap in knowledge can be attributed to the fact that traditional measures were developed using validation criteria that differ from the current standards in use. Consequently, additional validation studies in accordance with contemporary standards will be useful in aiding researchers and clinicians in determining the most suitable measure for assessing HRQL in patients with psoriasis.

Indexed as

Patient Reported Outcome MeasuresPsoriasisQuality of LifeHumansReproducibility of Results

Identifiers

PMID38265774
PMCPMC11096065
OpenAlexW4391167506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.